Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Share News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.25
Bid: 17.50
Ask: 19.00
Change: 0.00 (0.00%)
Spread: 1.50 (8.571%)
Open: 18.25
High: 18.25
Low: 18.25
Prev. Close: 18.25
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Scancell trial progresses; OptiBiotix inks new deal

Tue, 28th Nov 2023 14:57

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says two more patients have responded to its Scope study, which brings the number of responders to 11 out of 13 patients. As a result, the objective response rate has increased to 85%. Notes one patient has achieved a complete response following treatment. The study has transitioned into the second stage, and Scancell plans to recruit a further 27 patients, with the aim to achieve at least 18 further responses. The trial investigates Scancell's SCIB1 vaccination combined with checkpoint inhibitors in advanced melanoma. Scancell reported in mid-September that SCIB1 combined with checkpoint inhibitors showed an 82% objective response rate. Chief Executive Officer Lindy Durrant says: "The Scope study continues to yield excellent results with two more responders and one of the previous patients now achieving a complete response." Durrant says Scancell now expects the iSCIB1+ cohort to start in the first quarter of 2024."

----------

EnSilica PLC - Abingdon, Oxfordshire-based semiconductor designer and supplier - Says performance in the first half of the financial year ending May 31, has been "resilient", buoyed by continued business momentum and "significant" contracts with "key customers". Remains confident in near-to-medium term prospects. Expects to trade in line with market expectations for financial 2024. EnSilica says analyst consensus currently forecast revenue of GBP22.9 million and earnings before interest, tax, depreciation and amortisation of GBP2.5 million.

----------

Orosur Mining Inc - South America-focused minerals explorer and developer - Says Lithium West joint venture has obtained results from its mapping and sampling programme, noting that "abundant" pegmatites are evident, with lithium superoxide results in excess of 2%. Says two additional licences have been confirmed, with its land position in the key lithium districts expanded to 533 square kilometres. CEO Brad George says: "These outstanding results from our first field program in Nigeria are exciting but not surprising. We pegged these licences with a very clear understanding of the geological processes in play, and so we expected to find lithium. To then confirm this confidence and to find so many lithium bearing pegmatites, some extremely thick, is very positive and bodes well for work on the next 5 licences that is underway now."

----------

Zenith Energy Ltd - Africa and Italy-focused oil and gas company - Signs memorandum of understanding with Nile Services & Logistics Co Ltd to jointly pursue business opportunities involving the construction of fuel products storage tanks, pipelines, and crude oil storage tanks in South Sudan. Zenith will provide technical, financial and managerial expertise in the construction of the tanks, while Nile Services will facilitate business opportunities. Zenith CEO Andrea Cattaneo says: "We are very pleased to have now signed an MoU with Nile SLC, a subsidiary of the national oil company of South Sudan, and we look forward with enthusiasm to jointly exploring opportunities in the midstream domain and beyond, specifically with regards to petroleum product trading activities." Also confirms that it is currently in the advanced phase of negotiating the potential acquisition of oil exploration and development licences in South Sudan.

----------

OptiBiotix Health PLC - York, England-based life sciences company - Inks deal with Ravenswood Ingredients Pty Ltd for the distribution of SlimBiome in Australia and New Zealand. "Ravenswood brings access to the food and beverage markets and will complement existing partner capabilities which are largely focused on the meal replacement market to broaden OptiBiotix's impact in Australia and New Zealand. This is part of a strategy of building partnerships to support expansion of OptiBiotix's geographical footprint with companies who bring national and international capability for highly differentiated value-added ingredients in high growth markets around the world," it says. CEO Stephen O'Hara comments: "We are pleased to announce this agreement with Ravenswood who bring specialised food ingredient expertise as part of the Brenntag group, a global market leader in chemicals and ingredients distribution. This agreement is another example of OptiBiotix working with large partners and extends access to the food and beverage markets within Australia and New Zealand with a company which is part of a group which is a global leader in the ingredients market."

----------

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
7 May 2019 12:13

OptiBiotix inks LPLDL deal with Spain's IENP

(Sharecast News) - Life sciences business OptiBiotix Health announced on Tuesday that its wholly-owned subsidiary ProBiotix Health has signed a license agreement with Instituto Español de Nutrición Personalizada (IENP) for the use of 'lactobacillus plantarum' (LPLDL) in personalised food supplements in Spain.

Read more
29 Apr 2019 13:04

OptiBiotix Expects Further Growth After Annual Revenue Multiplies

LONDON (Alliance News) - OptiBiotix Health PLC on Monday reported a significant growth in revenue in its most recently ended financial year as it is on track to become a commercial life sciences a

Read more
24 Apr 2019 11:28

OptiBiotix to launch SlimBiome Medical in UK market this month

(Sharecast News) - Life sciences business OptiBiotix Health announced the launch of its weight management product 'SlimBiome Medical' to the UK market on Wednesday.

Read more
11 Apr 2019 11:16

OptiBiotix partner gets approval to make SlimBiome in India

(Sharecast News) - OptiBiotix Health announced on Thursday that it has received a licence from the Food Standards and Safety Authority India (FSSAI) for its weight management product 'SlimBiome' to be manufactured in the country.

Read more
9 Apr 2019 09:58

OptiBiotix Inks SlimBiome Distribution Pact For Bulgaria

LONDON (Alliance News) - OptiBiotix Health PLC on Tuesday said it has entered into a three-year deal with an undisclosed company to distribute and commercialise SlimBiome Medical in is used for a

Read more
20 Mar 2019 07:41

OptiBiotix inks deal with DKSH for Italy and Spain markets

(Sharecast News) - Life sciences company OptiBiotix Health has entered into an exclusive agreement with DKSH International to distribute its 'SlimBiome' proprietary weight management technology in Italy and Spain, it announced on Wednesday.

Read more
15 Mar 2019 08:16

Optibiotix Health expands international reach through supply agreement

(Sharecast News) - OptiBiotix Health on Friday extended a supply agreement to broaden the supply of cholesterol-lowering capsules into Germany and several other countries.

Read more
13 Mar 2019 16:08

OptiBiotix Health Secures GBP57,000 Following Warrants Exercise (ALLISS)

LONDON (Alliance News) - OptiBiotix Health PLC on Wednesday said it has raised GBP56,666 following an exercise of warrants.The life sciences company said 708,325 warrants were exercised at

Read more
21 Feb 2019 11:38

US FDA Finds OptiBiotix Health Cholesterol Probiotic Safe For Use

LONDON (Alliance News) - OptiBiotix Health PLC on Thursday said the US FDA assigned a GRAS designation to its cholesterol and blood pressure reducing probiotic strain.The Lactobacillus by a

Read more
21 Feb 2019 11:07

OptiBiotix up as LPLDL gets 'safe' status in US

(Sharecast News) - Life sciences firm OptiBiotix Health confirmed on Thursday that its wholly-owned subsidiary ProBiotix Health has had its cholesterol and blood pressure reducing 'Lactobacillus plantarum LPLDL' probiotic strain determined as 'Generally Recognized As Safe' (GRAS) by an independent expert GRAS panel in the United States.

Read more
13 Feb 2019 08:46

Optibiotix revenues soar in second half

(Sharecast News) - Optibiotix Health's annual income soared in its last trading year as the healthy food additive maker continued to commercialise its products and grow sales.

Read more
11 Feb 2019 12:32

OptiBiotix gains foothold in Japan with distibution deal

(Sharecast News) - Optibiotix Health on Monday signed an agreement appointing EIWA Trading Co. as its exclusive distributor for its cholesterol and blood pressure-reducing probiotic strain LPLDL in Japan.

Read more
11 Feb 2019 10:03

OptiBiotix Health Appoints EIWA To Distribute LPLDL Products In Japan

LONDON (Alliance News) - Life sciences company Optibiotix Health PLC said on Monday it has appointed EIWA Trading Co Ltd as the exclusive distributor for its LPLDL products in Japan.In EIWA

Read more
7 Feb 2019 10:40

OptiBiotix Health Inks Commercial Deal Covering Baltics With Biolat

LONDON (Alliance News) - OptiBiotix Health PLC on Thursday said it has entered a three-year supply agreement with Latvia-based firm Biolat JSC covering Estonia, Latvia and is a life sciences firm

Read more
9 Jan 2019 08:56

OptiBiotix extends CholBiome sales channel to Russia and Kazakhstan

(Sharecast News) - OptiBiotix Health on Wednesday entered into a three-year distribution agreement for its own-brand CholBiome products in Russia and Kazakhstan.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.